HomeCompareFSTX vs MRK

FSTX vs MRK: Dividend Comparison 2026

FSTX yields 28.09% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSTX wins by $61.7K in total portfolio value
10 years
FSTX
FSTX
● Live price
28.09%
Share price
$7.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$118.5K
Annual income
$14,804.06
Full FSTX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — FSTX vs MRK

📍 FSTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSTXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSTX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSTX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSTX
Annual income on $10K today (after 15% tax)
$2,387.64/yr
After 10yr DRIP, annual income (after tax)
$12,583.45/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, FSTX beats the other by $4,255.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSTX + MRK for your $10,000?

FSTX: 50%MRK: 50%
100% MRK50/50100% FSTX
Portfolio after 10yr
$87.6K
Annual income
$12,301.10/yr
Blended yield
14.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

FSTX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
0.7
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSTX buys
0
MRK buys
0
No recent congressional trades found for FSTX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSTXMRK
Forward yield28.09%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$118.5K$56.8K
Annual income after 10y$14,804.06$9,798.13
Total dividends collected$78.8K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: FSTX vs MRK ($10,000, DRIP)

YearFSTX PortfolioFSTX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$13,509$2,808.99$11,206$366.19+$2.3KFSTX
2$18,001$3,546.41$12,650$502.35+$5.4KFSTX
3$23,678$4,416.52$14,407$694.19+$9.3KFSTX
4$30,764$5,429.21$16,585$967.82+$14.2KFSTX
5$39,510$6,592.67$19,342$1,363.89+$20.2KFSTX
6$50,189$7,913.03$22,913$1,947.19+$27.3KFSTX
7$63,097$9,394.15$27,662$2,823.89+$35.4KFSTX
8$78,551$11,037.47$34,159$4,173.35+$44.4KFSTX
9$96,891$12,841.93$43,337$6,308.80+$53.6KFSTX
10$118,478$14,804.06$56,776$9,798.13+$61.7KFSTX

FSTX vs MRK: Complete Analysis 2026

FSTXStock

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Full FSTX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this FSTX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSTX vs SCHDFSTX vs JEPIFSTX vs OFSTX vs KOFSTX vs MAINFSTX vs JNJFSTX vs ABBVFSTX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.